Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy

This study was undertaken to investigate the role of mouse double minute 2 (MDM2) oncogene in prostate cancer growth and the potential of MDM2 as a target for prostate cancer therapy. An antisense anti-human–MDM2 mixed-backbone oligonucleotide was tested in human prostate cancer models with various p53 statuses, LNCaP (p53wt/wt), DU145 (p53mt/mt), and PC3 (p53null). In a dose- and time-dependent manner, it specifically inhibited MDM2 expression and modified expression of several genes, at both mRNA and protein levels. In LNCaP cells, p53, p21, Bax, and hypophosphorylated retinoblastoma tumor suppressor protein (pRb) levels increased, whereas Bcl2, pRb protein, and E2F transcription factor 1 (E2F1) levels decreased. In DU145 cells, p21 levels were elevated and E2F1 levels decreased, although mutant p53, Rb, and Bax levels remained unchanged. In PC3 cells, MDM2 inhibition resulted in elevated p21, Bax, and pRb levels and decreased ppRb and E2F1 levels. In all three cell lines, MDM2 inhibition reduced cell proliferation, induced apoptosis, and potentiated the effects of the chemotherapeutic agents 10-hydroxycamptothecin and paclitaxel. The anti-MDM2 oligonucleotide showed antitumor activity and increased therapeutic effectiveness of paclitaxel in both LNCaP and PC3 xenografts, causing changes in gene expression similar to those seen in vitro. In summary, this study demonstrates that MDM2 has a role in prostate cancer growth via p53-dependent and p53-independent mechanisms and that multiple genes are involved in the process. MDM2 inhibitors such as second-generation antisense oligonucleotides have a broad spectrum of antitumor activities in human cancers regardless of p53 status, providing novel approaches to therapy of human prostate cancer.

[1]  D. Wechsler,et al.  Mxi1, a Myc antagonist, suppresses proliferation of DU145 human prostate cells , 2001, The Prostate.

[2]  Dong Yu,et al.  Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed‐backbone antisense oligonucleotides: In vitro and in vivo activities and mechanisms , 2003, The Prostate.

[3]  K. Aozasa,et al.  p53 Mutations in Prostatic Intraepithelial Neoplasia and Concurrent Carcinoma: Analysis of Laser Capture Microdissected Specimens from Non‐transition and Transition Zones , 2000, Japanese journal of cancer research : Gann.

[4]  N. Mukaida,et al.  Nuclear factor-kappaB-dependent expression of metastasis suppressor KAI1/CD82 gene in lung cancer cell lines expressing mutant p53. , 2001, Cancer research.

[5]  Hui Wang,et al.  MDM2 oncogene as a novel target for human cancer therapy. , 2000, Current pharmaceutical design.

[6]  S. Agrawal,et al.  Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[7]  P. Zamecnik,et al.  Targeting the Mycobacterium tuberculosis 30/32-kDa mycolyl transferase complex as a therapeutic strategy against tuberculosis: Proof of principle by using antisense technology , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[8]  P. Tamboli,et al.  Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[9]  Matthew W. Strobeck,et al.  Differential requirements for ras and the retinoblastoma tumor suppressor protein in the androgen dependence of prostatic adenocarcinoma cells. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[10]  Jiandong Chen,et al.  Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  K. Ball,et al.  Differential post-translational modification of the tumour suppressor proteins Rb and p53 modulate the rates of radiation-induced apoptosis in vivo , 2001, Oncogene.

[12]  Miguel Srougi,et al.  Abnormal Expression of MDM2 in Prostate Carcinoma , 2001, Modern Pathology.

[13]  Thomas T. Y. Wang,et al.  Low‐dose genistein induces cyclin‐dependent kinase inhibitors and G1 cell‐cycle arrest in human prostate cancer cells , 2000, Molecular carcinogenesis.

[14]  S. Agrawal,et al.  Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[16]  C. Cordon-Cardo,et al.  Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. , 1999, Journal of the National Cancer Institute.

[17]  T. Cotter,et al.  Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions , 2001, British Journal of Cancer.

[18]  M. Ittmann,et al.  Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. , 1994, The American journal of pathology.

[19]  Hui Wang,et al.  Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  M. Day,et al.  RB activation and repression of C-MYC transcription precede apoptosis of human prostate epithelial cells. , 2001, Urology.

[21]  K. Honn,et al.  Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications. , 1997, Advances in experimental medicine and biology.

[22]  C. Cordon-Cardo,et al.  Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  A. Nakagawara,et al.  HMGB1 and HMGB2 Cell-specifically Down-regulate the p53- and p73-dependent Sequence-specific Transactivation from the Human Bax Gene Promoter* , 2002, The Journal of Biological Chemistry.

[24]  R. Schmid,et al.  Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma , 2000, Archives of Dermatological Research.

[25]  G. Stamp,et al.  Differential expression of cell death regulators in response to thapsigargin and adriamycin in Bcl‐2 transfected DU145 prostatic cancer cells , 2001, The Journal of pathology.

[26]  J. Yokota,et al.  Alterations in expression of E2F‐1 and E2F‐responsive genes by RB, p53 and p21 Sdi1/WAF1/Cip1 expression , 2001, FEBS letters.

[27]  E. Monti,et al.  The nitroxide tempol induces oxidative stress, p21(WAF1/CIP1), and cell death in HL60 cells. , 2000, Free radical biology & medicine.

[28]  E. Gelmann,et al.  Radiation-induced apoptosis mediated by retinoblastoma protein. , 1998, Cancer research.

[29]  A. Gewirtz,et al.  Nucleic-acid therapeutics: basic principles and recent applications , 2002, Nature Reviews Drug Discovery.

[30]  Ya‐Wen Cheng,et al.  MDM2 mRNA expression is a favorable prognostic factor in non‐small‐cell lung cancer , 2000, International journal of cancer.

[31]  Brigitte M Pützer,et al.  Gene expression changes in response to E2F1 activation. , 2002, Nucleic acids research.

[32]  D. Yap,et al.  Novel Function of the Cyclin A Binding Site of E2F in Regulating p53-Induced Apoptosis in Response to DNA Damage , 2002, Molecular and Cellular Biology.

[33]  R. Drouin,et al.  Ablation of p21waf1cip1 expression enhances the capacity of p53-deficient human tumor cells to repair UVB-induced DNA damage. , 2001, Cancer research.

[34]  J. Buolamwini,et al.  Antisense anticancer oligonucleotide therapeutics. , 2001, Current cancer drug targets.

[35]  C. Sheehan,et al.  Morphologic and Molecular Prognostic Markers in Prostate Cancer , 2002, Advances in anatomic pathology.

[36]  Q. Dou,et al.  Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[37]  N. Hay,et al.  A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function , 2001, Oncogene.

[38]  S. Crooke.  Potential roles of antisense technology in cancer chemotherapy , 2000, Oncogene.

[39]  S. Agrawal,et al.  Antisense and/or immunostimulatory oligonucleotide therapeutics. , 2001, Current cancer drug targets.

[40]  Xin Lu,et al.  RB regulates the stability and the apoptotic function of p53 via MDM2. , 1999, Molecular cell.

[41]  Yung-Hyun Choi,et al.  p53‐independent Induction of p21 (WAF1/CIP1), Reduction of Cyclin B1 and G2/M Arrest by the Isoflavone Genistein in Human Prostate Carcinoma Cells , 2000, Japanese journal of cancer research : Gann.

[42]  R. Franklin,et al.  Inhibitory effect of zinc on human prostatic carcinoma cell growth , 1999, The Prostate.

[43]  F. Mostofi,et al.  p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. , 1999, The Journal of urology.